The antimicrobial activity of metronidazole was investigated in anaerobic bacteria by use of time-viability studies. This antimicrobial agent has a rapid onset of bactericidal activity under proper reducing conditions. The bactericidal rates were not affected by inoculum size or nutritional requirements, nor by inhibition of growth and protein synthesis by chloramphenicol. Using supernatant fractions of actively growing cultures of susceptible organisms, we observed a disappearance of metronidazole and a loss of biological activity, but there was no significant change in preparations from resistant bacteria. The decrease in drug concentration with susceptible cells occurred during the time that its bactericidal action was being exerted. Extracts from susceptible organisms rapidly reduced the concentration of metronidazole, confirming previous observations which suggest that the drug acts as a terminal electron acceptor. Radioisotope experiments with ['4C]metronidazole revealed that the compound was taken up by both resistant and susceptible bacteria, although there was a difference in rate and extent of accumulation. These studies demonstrate that mentronidazole's antimicrobial activity against anaerobic bacteria is bactericidal and independent of growth rate, and that it involves the uptake and metabolism of the compound.
Metronidazole was first introduced into clinical medicine in 1959 for the treatment of Trichomonas vaginalis infections (2) , and it has been subsequently used for invasive amebiasis and giardiasis (4, 22) . Recent studies have documented its in vitro bactericidal activity against anaerobic bacteria (14) . Metronidazole appears to be efficacious in clinical anaerobic infections (18) , and two groups have reported its use prophylactically in gynecological and colonic surgery (6, 21) . The common denominator in these diverse indications is this antimicrobial agent's exclusive activity against anaerobic microorganisms.
The majority of published reports on the mechanism of action of metronidazole have concentrated on the effects in protozoa and tissue culture cells (3, 8, 19) . Our laboratory became interested in the drug because of its activity against clinically significant anaerobic bacteria. In addition, we thought that the rapid growth and simple culture requirements of anaerobic bacteria would make them excellent models for the investigation of metronidazole's antimicrobial action.
Preliminary studies of the activity of metronidazole in anaerobic bacteria have been carried out, but the results have been somewhat controversial. Ralph and Kirby suggested that metronidazole has a marked bactericidal effect which occurs after a prolonged lag phase (16) . There remains the possibility, however, that this prolonged lag period was an artifact ofmethodology. The purpose of our study was to investigate the antimicrobial activity of metronidazole on anaerobic bacteria, utilizing optimal anaerobic conditions, and to examine its uptake and disappearance in these microorganisms.
MATERIALS AND METHODS
Organisms. The anaerobic bacteria utilized in this study were isolated from clinical material processed in our laboratory and were identified according to the criteria of the Virginia Polytechnic Institute Anaerobic Manual (7). In addition, two Bacteroides fragilis isolates (K-1 and K-14) were obtained from William Kirby, Seattle, Wash. Minimal inhibitory concentrations (MICs) of metronidazole for these isolates were determined by previously described techniques (17 Activity on chloramphenicol-inhibited cells. The antimicrobial activity of metronidazole was studied in cells of B. fragilis inhibited by chloramphenicol to determine the effect of reduced protein synthesis on the bactericidal rate (5) . Cultures of B. fragilis were grown to early log phase in 200 ml of BHIS, and then each was equally divided into two tubes. Chloramphenicol was added to one of the tubes to give a final concentration of 8 pg/ml. After 2 additional h of incubation, the cultures were further divided into 50-ml portions, and metronidazole (10 pg/ml) was added to one of the control cultures and to one of the cultures containing chloramphenicol. Colony counts were obtained at 0, 2, 3, 4, 5, 6, and 24 h.
Assay for alteration of metronidazole. The resistant organism Escherichia coli 10 and the susceptible strain B. fragilis 8 were grown in minimal medium to early log phase, and 8 pg of metronidazole per ml was added to each culture flask. Control cultures in minimal medium were maintained under identical conditions. At 0, 5, 10, 20, 30, and 60 min, 5-ml samples were removed and centrifuged at 27,000 x g for 10 min; the supernatant fluids were removed and held at 4°C. After completion of the sampling, the concentration of drug in the medium supernatant fluid was determined spectrophotometrically at 320 and 340 nm (15) .
Metabolism of metronidazole by bacterial extracts. Bacterial extracts were prepared from the metronidazole-susceptible organisms B. fragilis 8 and Clostridium perfringens 41 and from the resistant organisms E. coli 10 and Propionibacterium acnes 121. The organisms were grown in 100 ml of BHIS into late log phase (approximately 109 CFU/ml) and were harvested under anaerobic conditions by centrifugation at 15,000 rpm for 20 min, with the use of plastic bottles with butyl rubber gaskets. The pellet was washed in the anaerobic chamber with 0.02 M dithiothreitol at pH 7 and was sonically treated. The sonic extract was reduced in the anaerobic chamber for 2 h.
The assay mixture contained 0.1 pmol of co-enzyme A, 60 pmol of pyruvate, 300 pmol of metronidazole, 0.5 umol of methyl viologen, and 0.4 ml of bacterial extract in a total volume of 3.8 ml. Control tubes containing various ingredients of the above mixture were included. All manipulations were carried out in the anaerobic chamber; test mixture and controls were incubated at 24°C for 2 h. The reaction mixture was centrifuged to remove cellular debris, and the supernatant fluid was used for spectrophotometric determination of the drug concentrations. Biological activity of the metronidazole in the supernatant fluid was determined by the agar well microbiological assay (9) . Protein concentrations were determined by the method of Lowry et al. (11) .
['4C]metronidazole uptake. The uptake of [14C]-metronidazole was studied in B. fragils and E. coli by use of PRAS (7) and anaerobic chamber techniques (1) . The location of the 14C radioactive tag in the hydroxyethyl side chain is shown in Fig. 1 . Pure cultures of B. fragilis and E. coli were separately inoculated into 100 ml of BHIS with cysteine (BHIS-C), incubated for 5 (Table 1) .
The drug had a prompt onset of bactericidal activity against the Bacteroidaceae (Fig. 2) . At 4 h after addition of the drug, there was a greater than 5-log decrease with seven isolates and 3-to 4-log decreases with the others. At 24 h, there was no growth with seven isolates, and there were fewer than 103 CFU/ml with three isolates. The two strains from Seattle, previously studied by Ralph and Kirby (16), were promptly killed with our techniques.
The bactericidal activity of metronidazole against clostridia was smilr to that against Bacteroidaceae (Fig. 3 ). There was a rapid onset of killing, with the colony counts decreasing 3 to 4 logs in 1 h.
Inoculum size of two strains of B. fragilis had no significant effect on metronidazole's bactericidal rate (Table 2) .
There were no signiicant differences in the bactericidal rates against three isolates of B.
fragilis grown in minimal versus enriched media. Figure 4 illustrates the rapid decrease in CFU of B. fragilis 464 grown in both media.
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by chloramphenicol had no effect on the bactericidal activity of metronidazole against B. fragilis (Fig. 5) . The organism was exposed to chloramphenicol for 2 h, and after the addition of metronidazole there was prompt bactericidal activity with a decrease of greater than 6 logs in both the rapidly growing and the chloramphenicol-inhibited cells. Effect of actively growing cells on the concentration of metronidazole. With a resistant strain of E. coli, the concentration of metronidazole decreased only 4 to 5% over a 60-min period (Fig. 6 ). However, with the susceptible B. fragilis strain, there was a greater than 90% decrease in the amount of drug measured spectrophotometrically. Concomitantly, there was a loss of biologically active drug in the medium from the B. fragilis culture as determined by the agar well diffusion assay, whereas there was no significant loss of bioactive drug in the E. coli culture.
Decrease in concentration of metronidazole by bacterial extracts. Metronidazole was incubated under anaerobic conditions with sonic extracts prepared from the susceptible organisms B. fragilis and C. perfringens, and there was a rapid reduction in the concentration of the drug (15 and 25 ,ug/h per mg of protein, respectively). However, there was no loss of the compound when it was exposed to sonic extracts from the resistant strains P. acnes and E. coli. This loss of metronidazole activity with susceptib: organisms was not observed with supernatant fluid from the sonic extracts nor when the sonic extracts were incubated in atmospheric oxygen.
In tubes contain g both methyl viologen and metronidazole, several minutes were required for sonic extracts of susceptible organisms to reduce the dye, indicated by formation of a blue color. Extracts incubated with methyl viologen in the absence of metronidazole displayed a rapid formation of the blue color. When metro- [14CJmetronidazole uptake. There was uptake of metronidazole by both the resistant E. coli and the susceptible B. fragilis grown under anaerobic conditions, although there were differences in the rate and extent (Fig. 7) . A rapid uptake of labeled drug (28%) by B. fragilis occurred during the first 2 h, during which time metronidazole is known to exert its bactericidal action. On the other hand, only 8% of the isotope was taken up by E. coli in 2 h.
DISCUSSION
The results of this study demonstrate that, under the proper reducing conditions, metronidazole has a rapid onset of bactericidal activity against susceptible anaerobic bacteria. These findings are divergent from those of Ralph and Kirby (16) , who showed a prolonged lag phase followed by a rapid decrease in viable cells. These investigators used anaerobic jar techniques which exposed the medium and organism to atmospheric oxygen, thus raising the oxidation reduction potential (Eh It is apparent that the activity of metronidazole is not affected by inoculum size, growth rate, or inhibition of protein synthesis. These findings may be explained by postulating that the antimicrobial activity of metronidazole is related to toxic intermediates produced during reduction of this compound (8) . The antimicrobial effect may be caused by interaction of these intermediates with deoxyribonucleic acid, and there is evidence that radioactive products of metronidazole bind deoxyribonucleic acid in protozoa (8) . Lindmark (10) . They have shown that the compound is taken up by susceptible anaerobic protozoa, a process which is oxygen sensitive (13) . Furthermore, they have demonstrated that the reduction of the nitro group on the imidazole ring is related to the compound's antimicrobial activity against Trichomonas and Clostridium. Our preliminary results indicate that the drug is taken up by both susceptible and resistant bacteria, but only the susceptible organisms seem capable of metabolizing the drug. This suggests that the biochemical events observed in protozoa may also be responsible for the activity against susceptible anaerobic bacteria. Further investigations of the mechanism of action of metronidazole may be facilitated by utizing B. fragilis because of its simple growth requirements and its adaptibility to methods for the study of macromolecular synthesis.
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